Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
AgeUp to 45
SponsorPeking University People's Hospital
About this trial
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Eligibility criteria
Qualifiers
Endometrioid adenocarcinoma G2, diagnosis by pathological.
The lesion is limited to the endometrium.
FIGO (2009) staging is IA.
Age less than 45.
Disqualifiers
The tumor has invaded the muscle layer.
FIGO (2009) stage IB or higher.
Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer
There are malignant tumors in other systems.
Trial design
Treatments tested in this trial
- Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Treatment groups
16 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov